WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Target to lower prices on basic goods in response to inflation
The black market dealers delivering Elon Musk's Starlink to US adversaries
Piece of 5,800lb battery pallet tossed from NASA's ISS crashes through Florida home
The Elle Woods effect: Good looking lawyers have more success in court, study finds
Children are evacuated from school 'during an exam' after threat made via email
I'm from Texas and live in the UK, these are all the weird things I've found about British people
Airplane passenger sparks furious debate about PETS flying in
Piece of 5,800lb battery pallet tossed from NASA's ISS crashes through Florida home
Yvette Fielding says her Most Haunted co
Hundreds fined, cars impounded at weekend street race meet
Nina Dobrev hospitalized with a neck brace due to serious e
McDonald's praised for innovative ad that smells exactly like classic item on their menu